Treating kids below four-year-old suffering from brain trauma with antibiotics can have a negative effect on their brain that has not yet developed, warns a study.
While there are no drugs available to treat these injuries, scientists have shown that certain antibiotics -- which inhibit the brain's inflammatory response -- can improve outcomes for adult animal models that have suffered a blow to the head.
According to Drexel University researchers in the US, when newborn rats administered immediately after a head injury, the FDA-approved antibiotic, minocycline, exacerbated cognitive deficits.
The study has appeared in the journal Experimental Neurology.
Those under age four, who experience brain trauma, can suffer lifelong problems with memory, attention and other executive functions.
"The developing brain is not the same as the fully mature brain," said lead author Ramesh Raghupathi.
"This study suggests that acute interventions targeting the inflammatory cascade may not be a viable strategy for treating traumatic brain injury in infants and young children," Raghupathi added.
The drug minocycline works by decreasing the activation of microglia -- the primary immune cells in the brain and spinal cord that protect against foreign pathogens.
They treated the newborn rats with minocycline -- one dose every day for three days -- they saw that their brain activity did not improve. When the researchers increased the dosage to nine days instead of three, the animal models showed significant memory problems and other behavioural deficits.
The findings indicated that the antibiotic had an adverse effect on the neonate rats, because microglia plays an important role during early brain development. These cells clear out dead neurons and debris to make a path for surviving neurons to function normally.
By targeting the microglia in the pediatric animal model, the antibiotics seemed to prevent the brain from undergoing its natural maturation process.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
